BioSpace News Archive

The Ivy Brain Tumor Center at Barrow Neurological Institute, the nation’s largest early-phase drug development program dedicated to brain cancer, is reporting initial results to the American Society of Clinical Oncology (ASCO) for two Phase 0 clinical trials of infigratinib and niraparib in recurrent high-grade glioma and newly-diagnosed glioblastoma, respectively.

Cytokinetics, Incorporated announced that on May 31, 2023 it granted stock options to purchase an aggregate of 76,800 shares of common stock to 7 new employees, whose employment commenced in May 2023, as a material inducement to their employment.

Adverum Biotechnologies, Inc. today announced that Laurent Fischer, M.D., president and chief executive officer will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York, New York.

Immutep Limited is pleased to announce the successful completion of an institutional placement and the institutional component of its 1 for 7.6 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.

Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib; CDK4/6 inhibitor) and Jaypirca™ (pirtobrutinib; non-covalent (reversible) BTK inhibitor) data to be presented at the 2023 ASCO® Annual Meeting in Chicago, June 2 – 6, 2023.

Octave today announced the presentation of new data on its MS-specific MRI Insights Program, Clinical Insights Program, and Protein Biomarker Program at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA® (valbenazine) capsules that demonstrated substantial and sustained improvements in tardive dyskinesia (TD) in adults with or without concomitant antipsychotic therapy.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. ET.

Terran Biosciences, Inc. has entered into an agreement with French pharmaceutical company Pierre Fabre Médicament S.A.S for worldwide exclusive rights to develop and commercialize a pipeline of Pierre Fabre’s assets to treat neuropsychiatric illnesses.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that management will present at the 2023 Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:00 a.m. ET.